Taysha Gene Therapies Inc... (TSHA)
Taysha Gene Therapies Statistics
Share Statistics
Taysha Gene Therapies has 205M shares outstanding. The number of shares has increased by 1.8% in one year.
| Shares Outstanding | 205M |
| Shares Change (YoY) | 1.8% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 62.39% |
| Shares Floating | 165.01M |
| Failed to Deliver (FTD) Shares | 85 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 25.53M, so 12.45% of the outstanding shares have been sold short.
| Short Interest | 25.53M |
| Short % of Shares Out | 12.45% |
| Short % of Float | 15.47% |
| Short Ratio (days to cover) | 15.45 |
Valuation Ratios
The PE ratio is -4.85 and the forward PE ratio is -2.89. Taysha Gene Therapies's PEG ratio is 0.08.
| PE Ratio | -4.85 |
| Forward PE | -2.89 |
| PS Ratio | 51.93 |
| Forward PS | 0.8 |
| PB Ratio | 6.05 |
| P/FCF Ratio | -5.3 |
| PEG Ratio | 0.08 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Taysha Gene Therapies.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.42, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.42 |
| Quick Ratio | 5.42 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | -0.2 |
| Debt / FCF | -0.21 |
| Interest Coverage | -896.66 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $114.15K |
| Profits Per Employee | $-1.22M |
| Employee Count | 73 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.78% in the last 52 weeks. The beta is 0.94, so Taysha Gene Therapies's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | -50.78% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 1.95 |
| Relative Strength Index (RSI) | 40.56 |
| Average Volume (20 Days) | 2.12M |
Income Statement
In the last 12 months, Taysha Gene Therapies had revenue of 8.33M and earned -89.3M in profits. Earnings per share was -0.36.
| Revenue | 8.33M |
| Gross Profit | 8.33M |
| Operating Income | -91.46M |
| Net Income | -89.3M |
| EBITDA | -87.95M |
| EBIT | -89.2M |
| Earnings Per Share (EPS) | -0.36 |
Balance Sheet
The company has 139.04M in cash and 17.36M in debt, giving a net cash position of 121.67M.
| Cash & Cash Equivalents | 139.04M |
| Total Debt | 17.36M |
| Net Cash | 121.67M |
| Retained Earnings | -602.3M |
| Total Assets | 160.36M |
| Working Capital | 115.9M |
Cash Flow
In the last 12 months, operating cash flow was -81.22M and capital expenditures -374K, giving a free cash flow of -81.6M.
| Operating Cash Flow | -81.22M |
| Capital Expenditures | -374K |
| Free Cash Flow | -81.6M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 100%, with operating and profit margins of -1097.55% and -1071.62%.
| Gross Margin | 100% |
| Operating Margin | -1097.55% |
| Pretax Margin | -1071.62% |
| Profit Margin | -1071.62% |
| EBITDA Margin | -1055.45% |
| EBIT Margin | -1097.55% |
| FCF Margin | -979.23% |
Dividends & Yields
TSHA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TSHA is $7, which is 451.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 451.2% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -4.41 |
| Piotroski F-Score | 3 |